e-ISSN 2460-7991

Challenge in diagnosis and management of lentigo maligna and lentigo maligna melanoma

Font Size:  Small  Medium  Large

Challenge in diagnosis and management of lentigo maligna and lentigo maligna melanoma

Ika Anggraini, Eliza Miranda, Larisa Paramitha Wibawa, Roro Inge Ade Krisanti, Adhimukti T. Sampurna

Abstract


Lentigo maligna (LM) is a subtype of melanoma in situ, which can evolve into lentigo maligna melanoma (LMM) if treated inadequately. LM and LMM are usually found on chronically sun damaged skin such as the face (cheek and nose) of the elderly on seventh or eight decades. Clinical manifestation of LM may be quite subtle, so early diagnosis is difficult to perform.The treatment of LM and LMM are challenging due to ill-defined clinical margin, predilection on the face with great size, and preponderance of the elderly, which are potential for recurrency and progressiveness from LM into LMM.

 

Keyword: lentigo maligna, lentigo maligna melanoma

 


Full Text: PDF

References


1. Bishop J. Lentigos, melanocytic nevi and melanoma. In: Burns T, editor. Rook's Textbook of Dermatology, 8th ed. United States: Wiley-Blackwell; 2013.p.2660-716.

2. Bosbous MW, Dzwierzynski WW, Neuburg M. Lentigo Maligna: Diagnosis and Treatment. Clin Plast Surg. 2010;37(1):35-46.

3. Bailey, Evans C. Cutaneous Melanoma. In: Goldsmith LA et al, editor. Fitzpatrick's Dermatology in General Medicine, 8th Ed. New York: Mc Graw Hill; 2012.p.1416-44.

4. Pratomo U. Gambaran histopatologi melanoma maligna. In: Cipto H; Djoerban Z; Suriadiredja AS, editor. Melanoma Dari Biologi Molekuler sampai dengan Penatalaksanaan. Jakarta: Balai Penerbit Fakutas Kedokteran Unversitas Indonesia; 2002.p.52-62.

5. Ferrari Junior NM, Muller H, Ribeiro M, Maia M, Sanches Júnior JA. Cutaneous melanoma: Descriptive epidemiological study. Sao Paulo Med J. 2008;126(1):41-7.

6. Anna B, Blazej Z, Jazqueline G, Andrew CJ JR. Mechanism of UV related carcinogenesis and its contribution to nevi/melanoma. Expert Rev Dermatol. 2007;2(4):451-69.

7. Shenenberger DW. Cutaneous malignant melanoma: A primary care perspective. Am Fam Physician. 2012;85(2):161-8.

8. Mc Kenna JK, Florell SR, Goldman GD, Bowen GM. Lentigo maligna/ lentigo maligna melanoma: Current state of diagnosis and treatment. Dermatologic Surg. 2006;32(4):493-504.

9. Kvaskoff M. Risk factors for lentigo maligna melanoma compared with superficial spreading melanoma. Arch Dermatol. 2012;148(2):164.

10. Stretch JR, Scolyer RA. Surgical strategies and histopathologic issues in the management of lentigo maligna. Ann Surg Oncol. 2009;16(6):1456-8.

11. 11.Swetter SM, Harvell JD. Increasing incidence of lentigo maligna melanoma subtypes: Northern California and national trends 1990-2000. J Invest Dermatol. 2005;125(4):685-91.

12. Mirzoyev SA, Knudson RM, Reed KB, Hou JL, Lohse CM, Frohm ML, et al. Incidence of lentigo maligna in Olmsted County, Minnesota, 1970-2007. J Am Acad Dermatol. 2014;70(3):443-8.

13. Suriadiredja AS, Kresno S, Cornain S. Biologi molekuler melanoma. In : Cipto H, Djoerban Z, Suriadiredja A, editor. Melanoma dari biologi molekuler sampai dengan penatalaksanaan. Jakarta: Balai Penerbit Fakutas Kedokteran Universitas Indonesia; 2002.p.1-11.

14. Purdue MP, From L, Kahn HJ, Amstrong BK, Kricker A, Gallagher RP, et al. Etiologic factors associated with p53 immunostaining in cutaneous malignant melanoma. Int J Cancer. 2005;117(3):486-93.

15. Miller AJ, Mihm MC. Mechanisms of disease melanoma. N Engl J Med. 2006;51-65.
16. Kraft S, Granter SR. Molecular pathology of skin neoplasms of the head and neck. Arch Pathol Lab Med. 2014;138(6):759-87.

17. El Ghissassi F, Baan R, Straif K, Grosse Y, Secretan B, Bouvard V, et al. A review of human carcinogens-Part D: radiation. Lancet Oncol. 2009;10(8):751-2. 

18. Boniol M, Autier P, Boyle P, Gandini S. Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis. Br Med J. 2012;345:4757.

19. Parkin DM. Cancers attributable to solar(ultraviolet) radiation exposure in the UK in 2010. Br J Cancer. 2011;105 Suppl(S2):S42-8.

20. Puig-Butillé JA, Carrera C, Kumar R, Garcia CZ, Badenas C, Aguilera P, et al. Distribution of MC1R variants among melanoma subtypes: p.R163Q is associated with lentigo maligna melanoma in a Mediterranean population. Br J Dermatol. 2013;169(4):804-11.

21. Kasprzak J, Xu Y. Diagnosis and management of lentigo maligna: a review. Drugs Context. 2015;4:1-16.

22. Kawasumi M. Ultraviolet radiation carcinogenesis. In: Goldsmith LA. Katz SI, Gilchrest BA, Paller AS LDW, editor. Fitzpatrick's dermatology in general medicine, 8th Ed. New York: Mc Graw Hill; 2012.p. 1287-97.

23. Hocker T. Tsao H. Ultraviolet radiation and melanoma: A systematic review and analysis of reported sequence variants. Hum Mutat. 2007;28(6):578-88.

24. Cohen Y, Rosenbaum E, Begum S, Goldenberg D, Esche C, Lavie O, et al. Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites. Clin Cancer Res. 2004;10(10):3444-7.

25. Gill M CJ. BRAF and melanocytic neoplasia. J Am Acad Dermatol. 2005;53(1):108-14.

26. Gaudy-Marqueste C, Madjlessi N, Guillot B, Avril M-F, Grob J-J. Risk factors in elderly people for lentigo maligna compared with other melanomas: a double case-control study. Arch Dermatol. 2009;145(4):418-23.

27. Lipsker D, Engel F, Cribier B, Velten M, Hedelin G. Trends in melanoma epidemiology suggest three different types of melanoma. Br J Dermatol. 2007;338-43.

28. Marmur ES. Reviewing challenges in the diagnosis and treatment of lentigo maligna and lentigo maligna melanoma. Rare Cancers Ther. 2015;133-45.

29. Alam M. Actinic keratoses: Prevalence, pathogenesis, presentation, and prevention. Johns Hopkins Advance Studies in Medicine. 2006;785-90.

30. Tanaka M, Sawada M, Kobayashi K. Key points in dermoscopic differentiation between lentigo maligna and solar lentigo. J Dermatol. 2011;38(1):53-8.

31. Bowling J. Diagnostic dermoscopy. The illustrated guide. Oxford: Wiley-Blackwell; 2012.

32. Farrahi F, Egbert BM, Swetter SM. Histologic similarities between lentigo maligna and dysplastic nevus: Importance of clinicopathologic distinction. J Cutan Pathol. 2005;32(6):405-12.

33. Juhl AL, Byers TE, Robinson WA, Moreli JG. The anatomic distribution of melanoma and relationship with childhood nevus distribution in Colorado. Melanoma Res. 2009;19(4):252-9.

34. Auslender S, Brazilai A, Goldberg I, Kopolovic J, Trau H. Lentigo maligna and superficial spreading melanoma are different in their in situ phase: An immunohistochemical study. Hum Pathol. 2002;33(10):1001-5.

35. Duncan LM. The Classification of cutaneous melanoma. Hematol Clin North Am. 2009;23(3):501-13.

36. Giacomel J, Lallas A, Argenziano G, Bombonato C, Zalaudek I. Dermoscopic ‘signature' pattern of pigmented and nonpigmented facial actinic keratoses. J Am Acad Dermatol. 2015;72(2):57-9. 

37. Kelley LC, Starkus L. Immunohistochemical staining of lentigo maligna during mohs micrographic surgery using MART-1. J Am Acad Dermatol. 2002;46(1):78-84.

38. Chang KH, Finn DT, Lee D, Bhawan J, Dallal GE, Rogers GS. Novel 16 minute technique for evaluating melanoma resection margins during Mohs surgery. J Am Acad Dermatol. 2011;64(1):107-12.

39. Magro C, Yang S, Zippin J, Zembowicz A. Expression of soluable adenyl cyclase (sAC) in lentigo maligna: Use of immunohistochemistry with anti-sAC antibody (R21), in diagnosis of lentigo maligna and assesment of margins. Arch Pathol Lab Med. 2012;136(12):1558-64.

40. Tsao H, Atkins MB, Sober AJ. Management of Cutaneous Melanoma. N Engl J Med. 2004;998-1012.

41. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199-206.

42. Kallini J, Jain S, Khachemoune A. Lentigo maligna. Review of salient characteristics and management. Am J Clin Dermatol. 2013;14(6):473-80.

43. Martinez JC, Otley CC. The management of melanoma and nonmelanoma skin cancer: a review for the primary care physician. Mayo Clin Proc. 2001;76(12):1253-65.

44. Carpenter S, Pockaj B, Dueck A, Gray R, Kurtz D, Sekulic A, et al. Factors influencing time between biopsy and definitive surgery for malignant melanoma: do they impact clinical outcome? Am J Surg. 2008;196(6):834-42

45. McKenna DB, Lee RJ, Prescott RJ, Doherty VR. The time from diagnostic excision biopsy to wide local excision for primary cutaneous malignant melanoma may not affect patient survival. Br J Dermatol. 2002;147:48-54

46. Bichakjian CK, Halpern AC, Johnson TM, Foote HA, Grichnik JM, Swetter SM, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2011;65(5):1032-47.

47. Bub JL, Berg, Daniel, Slee A, Odlan PB. Management of Lentigo Maligna and Lentigo Maligna Melanoma With Staged Excision. Arch Dermatol Res. 2004;140(5):552-8.

48. Mora AN, Karia PS, Nguyen BM. A quantitative systematic review of the efficacy of imiquimod monotherapy for lentigo maligna and an analysis of factors that affect tumor clearance. J Am Acad Dermatol. 2015;73(2):205-12.

49. Samaniego E, Redondo P. Lentigo Maligna. Actas Dermosifiliogr. 2011;147(10):1211-3.

50. Marghoob A, Koenig K, Bittencourt FV, Kopf AW, Bart RS. Breslow thickness and Clark level in melanoma. Cancer. 2000;88(3):589-95.

51. Ishihara K, Saida T, Otsuka F, Yamazaki N. Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update. Int J Clin Oncol. 2008;13(1):33-41.